RecruitingPhase 1NCT04913285

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.

Sponsor

Pierre Fabre Medicament

Enrollment

400 participants

Start Date

Aug 4, 2021

Study Type

INTERVENTIONAL

Conditions

Melanoma Non-small Cell Lung Cancer Solid Tumor, Adult

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called KIN-2787 and a drug called KIN-2787 and binimetinib for people with melanoma, non-small cell lung cancer, and other related conditions. The study is currently recruiting participants at 48 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGKIN-2787

KIN-2787 will be administered orally twice daily in 28-day cycles

DRUGKIN-2787 and binimetinib

Continuous and Ramp-Up cohorts: KIN-2787 (exarafenib) and binimetinib will be administered orally twice daily in 28-day cycles Intermittent Cohort: KIN-2787 will be administered orally twice daily and binimetinib will be administered twice daily for 5 days on, 2 days off for 28-day cycles

Locations(48)

The Angeles Clinic

Los Angeles, California, United States

UCLA

Los Angeles, California, United States

University of California San Diego, Moores Cancer Center

San Diego, California, United States

University of California San Francisco

San Francisco, California, United States

Sarah Cannon Research Institute Denver

Denver, Colorado, United States

Mayo Clinic - Florida

Jacksonville, Florida, United States

Sarah Cannon Research Institute - Florida Cancer Specialists

Orlando, Florida, United States

Mayo Clinic - Rochester

Rochester, Minnesota, United States

Atlantic Health

Morristown, New Jersey, United States

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, United States

NYU Langone

New York, New York, United States

Cleveland Clinic

Cleveland, Ohio, United States

Sarah Cannon Research Institute-Tennessee Oncology

Nashville, Tennessee, United States

MD Anderson

Houston, Texas, United States

Virginia Cancer Specialists

Fairfax, Virginia, United States

Calvary Mater Hospital Newcastle

Waratah, New South Wales, Australia

Melanoma Institute Australia

Wollstonecraft, New South Wales, Australia

Tasman Health Care

Southport, Queensland, Australia

Austin Health

Heidelberg, Victoria, Australia

Linear Clinical Research

Perth, Western Australia, Australia

Harbin Medical University Cancer Hospital

Haerbin, Heilongjiang, China

Linyi Cancer Hospital

Linyi, Shandong, China

Beijing University Cancer Hospital

Beijing, China

The Shanghai Pulmonary Hospital

Shanghai, China

Institut Bergonie

Bordeaux, France

Centre Francois Baclesse

Caen, France

CHU de Lille

Lille, France

Centre Leon Berard

Lyon, France

APHM-CHU La Timone

Marseille, France

CHU Nantes-Hotel Dieu

Nantes, France

CHU de Nice - Hôpital Archet 2

Nice, France

APHP - Hôpital St Louis

Paris, France

Hospices Civiles de Lyon - Hôpital Lyon Sud

Pierre-Bénite, France

CHU de Poitiers

Poitiers, France

Oncopole Claudius Regaud

Toulouse, France

Gustave Roussy

Villejuif, France

Istituto Nazionale dei Tumori Fondazione G. Pascale

Naples, Italy

Arance

Barcelona, Spain, Spain

NEXT Quirónsalud Madrid

Madrid, Spain, Spain

H. Regional de Málaga

Málaga, Spain, Spain

H. Virgen Macarena

Seville, Spain, Spain

Berrocal

Valencia, Spain, Spain

Hospital Quiron Dexeus

Barcelona, Spain

Hospital Universitario Insular de Gran Canaria

Las Palmas de Gran Canaria, Spain

START Madrid

Madrid, Spain

Hospital General Gregorio Marañón

Madrid, Spain

INCLIVA (Hospital Clinico de Valencia)

Valencia, Spain

National Taiwan University Hospital

Taipei, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04913285

Related Trials

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

NCT040386191 location

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

NCT063984181 location

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

NCT06767514270 locations

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738312 locations

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

NCT076597823 locations